Cobimetinib in malignant melanoma: how to MEK an impact on long-term survival

Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF -mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial

(2018) Reinhard Dummer et al.   LANCET ONCOLOGY

Binimetinib versus dacarbazine in patients with advanced NRAS -mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial

(2017) Reinhard Dummer et al.   LANCET ONCOLOGY

Management of Treatment‐Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma

(2017) Adil Daud et al.   ONCOLOGIST

MEK inhibitor-associated retinopathy (MEKAR) in metastatic melanoma: Long-term ophthalmic effects

(2016) U. Urner-Bloch et al.   EUROPEAN JOURNAL OF CANCER

MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade

(2016) Peter J.R. Ebert et al.   IMMUNITY

Immunomodulating property of MAPK inhibitors: from translational knowledge to clinical implementation

(2016) Mario Mandalà et al.   LABORATORY INVESTIGATION

Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial

(2016) Paolo A Ascierto et al.   LANCET ONCOLOGY

Genomic Classification of Cutaneous Melanoma

(2015) Rehan Akbani et al.   CELL

PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor-Treated Melanoma Patients

(2015) H. Kakavand et al.   CLINICAL CANCER RESEARCH

Phase I Dose-Escalation Trial of Checkpoint Kinase 1 Inhibitor MK-8776 As Monotherapy and in Combination With Gemcitabine in Patients With Advanced Solid Tumors

(2015) Adil I. Daud et al.   JOURNAL OF CLINICAL ONCOLOGY

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

(2015) Georgina V Long et al.   LANCET

Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Transient MEK inhibitor-associated retinopathy in metastatic melanoma

(2014) U. Urner-Bloch et al.   ANNALS OF ONCOLOGY

BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact

(2014) H. Rizos et al.   CLINICAL CANCER RESEARCH

Combination of vemurafenib and cobimetinib in patients with advanced BRAFV600-mutated melanoma: a phase 1b study

(2014) Antoni Ribas et al.   LANCET ONCOLOGY

Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma

(2014) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Inhibition of both BRAF and MEK in BRAFV600E mutant melanoma restores compromised dendritic cell (DC) function while having differential direct effects on DC properties

(2013) Patrick A. Ott et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Effect of inhibition of the FGFR–MAPK signaling pathway on the development of ocular toxicities

(2013) Ruud van der Noll et al.   CANCER TREATMENT REVIEWS

BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma

(2013) D. T. Frederick et al.   CLINICAL CANCER RESEARCH

Pharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients With Metastatic Melanoma

(2013) Kerstin Trunzer et al.   JOURNAL OF CLINICAL ONCOLOGY

MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study

(2013) Paolo A Ascierto et al.   LANCET ONCOLOGY

Absolute Bioavailability and Effect of Formulation Change, Food, or Elevated pH with Rabeprazole on Cobimetinib Absorption in Healthy Subjects

(2013) Luna Musib et al.   MOLECULAR PHARMACEUTICS

Tumor adaptation and resistance to RAF inhibitors

(2013) Piro Lito et al.   NATURE MEDICINE

A Landscape of Driver Mutations in Melanoma

(2012) Eran Hodis et al.   CELL

Bridging the Gap between Preclinical and Clinical Studies Using Pharmacokinetic-Pharmacodynamic Modeling: An Analysis of GDC-0973, a MEK Inhibitor

(2012) H. Wong et al.   CLINICAL CANCER RESEARCH

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

(2012) Axel Hauschild et al.   LANCET

Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma

(2012) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma

(2011) James S. Wilmott et al.   CLINICAL CANCER RESEARCH

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K

(2010) Jessie Villanueva et al.   CANCER CELL

Selective BRAFV600E Inhibition Enhances T-Cell Recognition of Melanoma without Affecting Lymphocyte Function

(2010) A. Boni et al.   CANCER RESEARCH